Bullfrog ai partners with j. craig venter institute to develop colorectal cancer therapeutic

Collaboration seeks to develop an oncolytic virus that incorporates a novel, precision-targeted approach to improve safety and efficacy gaithersburg, md / accesswire / february 23, 2023 / bullfrog ai holdings, inc. (nasdaq:bfrg; bfrgw) ("bullfrog ai" or the "company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced a co-development arrangement with the j. craig venter institute (jcvi), a world-leading institution in genomics research and innovation, for the design and validation of a synthetic hsv-1 (herpes simplex type 1) virus particle targeting colorectal cancer.
BFRG Ratings Summary
BFRG Quant Ranking